Simulations Using a Drug-disease Modeling Framework and Phase 2 Data Predict Phase 3 Survival Outcome in First-line Non-small Cell Lung Cancer
Year: November 1, 2012
Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.